Get In Touch

Acute Viral Rhinosinusitis Treatment Market to Cross Valuation of US$ 3.16 Bn by 2031: Transparency Market Research

Acute Viral Rhinosinusitis Treatment Market: Introduction

According to the report, the global acute viral rhinosinusitis treatment market was valued over US$ 1.78 Bn in 2020 and is projected to expand at a CAGR of 5.3% from 2021 to 2031. The term acute rhinosinusitis (ARS) refers to a symptomatic inflammation of the nasal cavity and paranasal sinuses that lasts less than four weeks. As inflammation of the sinuses seldom occurs without infection of the nasal mucosa, the name rhinosinusitis is favored over sinusitis. A viral infection is the most prevalent cause of ARS. The global acute viral rhinosinusitis treatment market is anticipated to be driven by increase in rhinosinusitis cases. Rhinosinusitis accounted for 12 million to 17 million yearly physician visits and 12% of antibiotics administered to senior patients in the U.S., making it one of the top 10 diseases treated in ambulatory practice. The global acute viral rhinosinusitis treatment market is expected to be driven by the increase in the incidence of acute rhinosinusitis.

North America dominated the global acute viral rhinosinusitis treatment market in 2020, and the trend is anticipated to continue during the forecast period. Acute viral rhinosinusitis is characterized by rapid exacerbation or emergence of symptoms in a patient with chronic sinusitis, which is usually accompanied with purulence draining from the sinuses as shown on nasal endoscopy.

Surge in healthcare expenditure and rise in awareness about sinusitis are expected to fuel the growth of the market in Asia Pacific. The market in the region is likely to be driven by increase in investment in R&D of pharmaceutical drugs.

The market in Europe is projected to be driven by increase in demand for drugs for the treatment of acute viral rhinosinusitis. Additionally, increase in awareness about acute viral rhinosinusitis and focus on discovering novel treatment drugs are anticipated to propel the market in the region.

Antibiotics to be Preferred for Treatment of Dominate Acute Viral Rhinosinusitis Treatment Market

In terms of treatment type, the global acute viral rhinosinusitis treatment market has been classified into saline nasal spray, nasal corticosteroids, decongestants, NSAIDs, and others. The NSAIDs segment dominated the global market in 2020 due to increase in prescription of antibiotics for acute viral rhinosinusitis by physicians.

Oral Most Commonly Used Route of Administration

Based on route of administration, the global acute viral rhinosinusitis treatment market has been categorized into topical, nasal, oral, and injectable. The oral segment dominated the global market in 2020, as it is a cost-effective, convenient, and most commonly used medication administration route compared to other routes.

North America to Dominate Global Market

The global market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America held the largest share of the global acute viral rhinosinusitis treatment market in 2020. The growth of the acute viral rhinosinusitis treatment market in North America can be attributed to the increase in incidence of rhinosinusitis in the U.S. Hence, the global acute viral rhinosinusitis treatment market is expected to be driven by increase in the number of acute rhinosinusitis cases.

The acute viral rhinosinusitis treatment market in North America is likely to expand at a high CAGR from 2020 to 2030. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players are anticipated to drive the acute viral rhinosinusitis treatment market in the region.

Competition Landscape

The study presents profiles of leading players in the global acute viral rhinosinusitis treatment market. These include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.

The top players in the global acute viral rhinosinusitis treatment market focus on improving the distribution network and expanding their product portfolio to increase market share. On July 26, 2020, Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending the approval of Xolair (omalizumab) as an add-on therapy to intranasal corticosteroids (INC) for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom INC therapy does not provide enough relief. If authorized, omalizumab would be the first nasal polyps therapy to target and inhibit immunoglobulin E (IgE), which helps to reduce the size of nasal polyps (as measured by the Nasal Polyps Score; NPS) and relieve symptoms.

Global Acute Viral Rhinosinusitis Treatment Market: Segmentation

  • Acute Viral Rhinosinusitis Treatment Market, by Treatment
    • Saline Nasal Spray
    • Nasal Corticosteroids
      • Fluticasone
      • Budesonide
      • Mometasone
      • Others
    • Decongestants
      • Topical Decongestants
      • Systemic Decongestants
    • NSAIDs
      • Acetaminophen
      • Ibuprofen
      • Aspirin
      • Others
    • Others
  • Acute Viral Rhinosinusitis Treatment Market, by Route of Administration
    • Topical
    • Nasal
    • Oral
    • Injectable
  • Global Acute Viral Rhinosinusitis Treatment Market, by Distribution Channel
    • Online Pharmacies
    • Retail Pharmacies
    • Hospital Pharmacies
  • Acute Viral Rhinosinusitis Treatment Market, by Infection Type
    • Rhinovirus (Picornavirus)
    • Non-Rhinovirus
      • Influenza
      • Enterovirus
      • Adenovirus
      • Others
  • Acute Viral Rhinosinusitis Treatment Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com/

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC